Is This Medical-Device-Making Dividend Aristocrat a Buy?

The two most telling indications of a quality dividend stock are earnings that consistently increase and dividends that grow along with that growing bottom line. Medtronic (NYSE: MDT) meets both of these criteria, and the S&P 500 component has raised its payout annually for 44 consecutive years, handily qualifying it for the status of Dividend Aristocrat.

But is the stock a buy at its current price?

Let's take a look at Medtronic's solid operating results for the start of its fiscal 2022 (which will end in April), its balance sheet, and its valuation to answer this question.

Continue reading

Source Fool.com